Autologous graft versus myeloma: it’s not a myth
Shuai Dong and Irene M. Ghobrial
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Address correspondence to: Irene M. Ghobrial, Harvard Institute of Medicine Room 240, 4 Blackfan Circle, Boston, Massachusetts 02115, USA. Phone: 617.632.6777; Email: Irene_Ghobrial@DFCI.harvard.edu.
Find articles by
Dong, S.
in:
JCI
|
PubMed
|
Google Scholar
|
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Address correspondence to: Irene M. Ghobrial, Harvard Institute of Medicine Room 240, 4 Blackfan Circle, Boston, Massachusetts 02115, USA. Phone: 617.632.6777; Email: Irene_Ghobrial@DFCI.harvard.edu.
Find articles by Ghobrial, I. in: JCI | PubMed | Google Scholar
First published November 19, 2018 - More info
J Clin Invest. 2019;129(1):48–50. https://doi.org/10.1172/JCI125431.
Copyright © 2019, American Society for Clinical Investigation
Graft-versus-tumor (GVT) effects have been thought to mostly result from allogeneic transplants; however, there is a growing body of research that supports a possible autologous GVT effect. In early clinical studies, a positive correlation between lymphocyte count recovery after autologous transplantation and overall survival has been observed. However, mechanistic studies to identify the mediators of autologous GVT responses have been lacking. In this issue of the JCI, Vuckovic et al. observed a T cell–dependent autologous GVT effect in the Vk*MYC myeloma model. Moreover, the authors showed that CD8+ T cells mediate myeloma control through IFN-γ secretion, which could be further augmented with a CD137 agonist, suggesting a therapeutic approach for enhancing autologous GVT.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- Print subscription
- $830
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)